Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
SUNNYVALE, Calif., May 18, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that a clinical abstract on our Btk inhibitor, PCI-32765, has been selected for an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011 in Chicago, IL. Additionally, two clinical abstracts on PCI-32765 have been selected for oral presentations at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 15-18, 2011.
Pharmacyclics plans to present a material update on the PCI-32765 clinical development program in a press release after the ASCO oral presentation on Monday, June 6, 2011 and expects to hold a conference call as well. The update will encompass the entire PCI-32765 clinical development program and will specifically include: 1) safety and efficacy data with the use of single-agent PCI-32765 in relapsed/ refractory or treatment-naive chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL) in patients with adequate follow-up from our ongoing Phase IB/II trial, including patients with poor-risk disease; 2) an update of efficacy from the Phase 1A trial of PCI-32765 in B-cell malignancies, including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 3) a status update for ongoing PCI-32765 clinical studies, including a pilot trial of PCI-32765 in the ABC subtype of diffuse large B-cell lymphoma, a phase II trial of single agent PCI-32765 in mantle cell lymphoma, and studies with PCI-32765 in combination with either bendamustine/rituximab (BR), fludarabine/cyclophosphamide/rituximab (FCR), or ofatumumab in CLL.
Oral Abstract Data Presentation at ASCO, Chicago (June 3 — 7, 2011)
Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.
Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM — 12:30 PM
Session Title: Leukemia, Myelodysplasia and Transplantation
Location: Arie Crown Theater
Oral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)
Abstract # 122
Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study. S. O'Brien et al.
Date/Time: Friday, June 17, 2011; 9:45 AM
Session 10: Chronic Lymphocytic Leukemia (CLL)
Location: Room A, B, C and Marquee Parco Ciani)
Abstract # 153
Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study. R.H. Advani et al.
Date/Time: Saturday, June 18, 2011; 9:30 AM
Session 14: Signaling Pathways in Lymphoma
Location: Room A
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.
SOURCE Pharmacyclics, Inc.
Posted: May 2011